### **Current Evidence in Ovarian Reserve - PCOS**



#### **Dr. Rana Choudhary**

(MBBS, DNB, DGO, DFP, FCPS, FICMCH, FICOG, MNAMS) Masters in Reproductive Medicine (UK) Diploma in Clinical Research

#### DESIGNATION:

- Consultant Obstetrician & Gynaecologist
- Reproductive Medicine Specialist
- Wockhardt hospital & Ankoor Fertility Clinic (Mumbai)

#### AWARDS:


- FOGSI Future award, FOGSI Shanti Yadav award for Infertility,
- FOGSI Imaging science award
- MOGS Dr Pramila Bhatia Young Scientist award & Dr. H. Desa award
- Best Scientific paper award at various conferences

**<u>PUBLICATIONS</u>**: National & international publications

Peer reviewer of National & International journals

<u>SPECIAL INTERESTS</u>: Reproductive medicine & Infertility

### Introduction



Dr. Rana Choudhary

### **Ovarian Reserve**

Functional potential of ovary; reflects the number & quality of oocytes within it.

- Quantity of oocytes (ovarian age)
- Quality of oocytes (chronological age)

#### **Ovarian Reserve**

- **Ovarian reserve** Determine capacity of ovary to provide oocytes that are capable of fertilization resulting in a healthy & successful pregnancy
- Complex clinical phenomenon influenced by age, genetics & environmental variables
- Decline is irreversible & Rate varies considerably
- Ovarian reserve markers serve as a proxy for oocyte quantity but are considered poor predictors of oocyte quality

Dr. Rana Choudhary

#### Indications for ovarian reserve testing

Women undergoing infertility evaluation/treatment

Individualization of assisted reproductive technology ovarian stimulation protocol and dosing

History of premature ovarian failure (insufficiency) or early menopause

Polycystic ovarian syndrome

Women considering elective (social egg) freezing

Oocyte donors

Fertility preservation before and after gonadotoxic treatment

Preoperative prior to ovarian surgery in reproductive-age women

Diagnosis and recurrence surveillance for granulosa cell tumors

Perimenopause

Women with BRCA-1 or FMR1 premutation

BRCA-1, breast cancer gene-1; FMR1, fragile X mental retardation 1.

Dr. Rana Choudhary

### **ORT – Whom & Why?**

#### WHOM:

- General Population
- Subfertile women

• IVF

#### WHY:

Informed decision about

childbearing

- Planning rapidity & mode of Rx
- Assess response & probability of

pregnancy

• Limit attempts or exclude

### **Markers of Ovarian Reserve**

<u>Age</u> -> 36 Years (Basic Marker)

#### **Basal Hormones**

- **1. FSH** (Scott et al., 1989; Toner et al., 1991)
- 2. Inhibin B (Hall et al., 1999)
- **3.** Anti-Mullerian Hormone (AMH)

(van Rooij et al., 2002)

4. Oestradiol

#### Sonographic Parameters

- **1.** Antral follicle count(AFC) (Bancsi et al., 2002; van Rooij et al., 2002)
- 2. Ovarian volume
- 3. Ovarian vascular flow

#### **Challenge tests/Dynamic tests**

- Clomiphene citrate challenge test (CCCT)
- 2. GnRH agonist stimulation test (GAST) (Winslow et al., 1991)
- Exogenous FSH ovarian reserve test (EFORT) (Fanchin et al., 1994)
   Dr. Rana Choudhary

### **Ideal ORT**

- Predict conception (with or without treatment)
- Predict the time of onset of ovarian ageing
- Guide in selection of optimal dose of gonadotropins
- Easily measurable, minimally invasive, inexpensive & good predictive value
- Minimize risk of wrongly diagnosing as DOR
- Accurately identify those at greatest risk of developing OHSS
- Identify patients who will have poor response


Dr. Rana Choudhary

Reshef Tal et al. Ovarian reserve testing: a user's guide. AJOG. August **2017.** Padma Rekah Jirge. Ovarian reserve tests. J Hum Reprod Sci. Dec **2011** 

### Age

- Ovarian reserve reduces progressively with age
- Most important factor determining pregnancy potential in regularly cycling women
- Age still remains the best predictor of oocyte quality in
- Chronological age alone has a limited value in predicting individual ovarian responses


Figure 5.1 The effect of maternal age on the average rate of pregnancy, calculated on the basis of studies in10 different populations that did not use contraceptives (adapted from Heffner, 2004, based on two reviews by Menken et al, 1986, and Anderson et al, 2000)





#### **Ovarian reserve = Composite of follicle number & oocyte quality**

(te Velde and Pearson, 2002)




Change in fertilizability & Implantation potential

**1** risk of embryonic chromosomal abnormalities

**†** Spontaneous abortions

## Quantitative (solid line) & qualitative (dotted line) decline of ovarian follicle pool, which is assumed to dictate onset of important reproductive events



Broekmans, F.J. et al. Hum Reprod Update **2006** 

# Comparison of ovarian reserve markers follicle-stimulating hormone, antral follicular count, and antimüllerian hormone

Test	Basal FSH	AFC	AMH 2002	
Year described	1988	1997		
Timing	Day 2–5 of menstrual cycle	Day 2–5 of menstrual cycle	Any day	
Temporal change indicating ovarian aging	Latest	Early	Earliest	
Intracycle variability	Clinically significant	Clinically significant	Minimal	
Intercycle variability	Clinically significant	Clinically significant Minimal		
Methodology	Automated	Ultrasound	ELISA/automated	
Cost, \$	95—125	300-500	76—95	
			Dr. Rana Choudhary	


## Comparison of ovarian reserve markers follicle-stimulating hormone, antral follicular count, and antimüllerian hormone

Test	Basal FSH	AFC	АМН	
Advantages	Widespread use		Immediate results; good predictive value for stimulation ovarian response, including predicting OHSS	Reliable; high sensitivity; good predictive value for stimulation ovarian response, including predicting OHSS
Limitations	Reliability; low sensitivity; dependent on functional HPO axis; less precision due to intercycle and intracycle variability; does not predict OHSS		Interobserver variability (sonographer-dependent); requires cost of ultrasound technician and availability of ultrasound machine; significant intercycle variation in overweight and obese	Lack of international standardized assay; requires careful sample preparation and storage Dr. Rana Choudhary

## Comparison of ovarian reserve markers follicle-stimulating hormone, antral follicular count, and antimüllerian hormone

Test	Basal FSH	AFC	AMH
Cut-offs used for determining sensitivities and specificities	10—20 IU/L	<3-4 follicles (total)	0.1—1.66 <sup>a</sup> ng/mL or <0.1—<0.3 <sup>b</sup> ng/mL
Sensitivity for poor response, %	11—86 <sup>15</sup>	9-73 <sup>15</sup>	44—97 <sup>4</sup>
Specificity for poor response, %	45—100 <sup>15</sup>	73—97 <sup>15</sup>	41-100 <sup>4</sup>
AUC for poor response	0.68 (95% Cl 0.61-0.74) <sup>42</sup>	0.76 (95% CI 0.70-0.82) <sup>42</sup>	0.78 (95% CI 0.72-0.84)42
Sensitivity for nonpregnancy, %	3—65 <sup>15</sup>	7–34 <sup>15</sup>	19—66 <sup>32</sup>
Specificity for nonpregnancy, %	50—100 <sup>15</sup>	64—98 <sup>15</sup>	55—89 <sup>32</sup> Dr. Rana Choudhary


#### **Expression of OR markers**



### Which ovarian reserve test to choose?

#### • AMH & AFC > FSH

- AMH Direct product of both cumulus & mural granulosa cells from preantral & small antral follicles during early folliculogenesis
   Section through Ovarian Follicle<sup>3</sup>
- AMH will decline years prior to a rise in FSH
- Earlier, More sensitive , Real time biomarker
- Greater correlation with primordial follicle pool
- Indirect markers FSH



Reshef Tal et al. Ovarian reserve testing: a user's guide. AJOG. August 2017

Fig. 1: AMH production


### **Conclusion & Recommendations**


- Do not use : Ovarian volume, ovarian blood flow, inhibin B, oestradiol (E2)
- **Ovarian reserve curves** similar to antenatal growth charts
- Can help identify patients who will have poor response / hyper response to OI for ART
- Individualize treatment protocols Optimal response & Minimizing safety risks
- Reproductive lifespan & menopausal timing
- Aid in counseling & treatment strategy planning Young female cancer patients
- Currently no perfect ovarian reserve test
- AFC & AMH Good predictive value

Dr. Rana Choudhary

Fertility problems: Assessment and treatment. NICE Reference Clinical guideline [CG156]. Feb 2013. Last updated: Sept 2017

#### Which tests are best in PCOS?





### **Diagnosis of PCOS**

- Rotterdam consensus meeting (2003 ESHRE/ASRM)
- Presence of at least two of three criteria with exclusion of other causes of menstrual cycle disturbance or androgen excess
- ✓ Oligo-ovulation and/or anovulation,
- ✓ Hyperandrogenism (clinical and/or biochemical)
- ✓ Polycystic ovaries on USG

Dr. Rana Choudhary

Fertility problems: Assessment and treatment. NICE Reference Clinical guideline [CG156]. Feb 2013. Last updated: Sept 2017

### **AFC in PCOS**

- Ultrasound criteria Significant operator & Instrument variability
- 12 or more follicles, 2–9 mm in diameter in follicular phase & Ovarian volume >10 cm<sup>3</sup>
- Follicle number per ovary (FNPO) = 18 (>8 MHz ultrasound probes)
- International PCOS Guidelines 2018 FNPO ≥20 &/or ovarian volume ≥10 ml
- Asian PCOS women have a lower FNPO

#### Dr. Rana Choudhary

Mahajan N et al. Establishing an Anti-Müllerian hormone cutoff for diagnosis of polycystic ovarian syndrome in women of reproductive age-bearing Indian ethnicity using automated AMH assay. J Hum Reprod Sci. June 2019

### **AMH in PCOS**


#### <u>AMH - surrogate marker for PCOM instead of AFC</u>

- > 30 years AMH better predictor than FNPO
- AMH 2–3-folds higher than in non-PCOS healthy women

Dr. Rana Choudhary


Mahajan N et al. Establishing an Anti-Müllerian hormone cutoff for diagnosis of polycystic ovarian syndrome in women of reproductive age-bearing Indian ethnicity using automated AMH assay. J Hum Reprod Sci. June 2019

### What regulates entry of follicles into growing pool



Dr. Rana Choudhary

Dumont et al. Role of AMH in pathophysiology, diagnosis & treatment of PCOS: a review. Reproductive Biology and Endocrinology. **2015** 



Dumont et al. Role of AMH in pathophysiology, diagnosis & treatment of PCOS: a review. Reproductive Biology & Endocrinology. **2015** 

### **Optimum cut off values for AMH in PCOS**

- AMH levels in women with PCOS (phenotype A) was significantly higher than the other phenotypes
- Phenotype A Highest risk of OHSS
- Caucasian population : AMH 3.5 ng/ml to 8.4 ng/ml

Author	Ethnicity	Year	AMH assay	AMH cut off (ng/ml)	AUC	Sensitivity (%)	Specificity (%)
	55			2010-00-022			
Pigny et al.	Caucasian	2006	IOT	8.4	0.851	67	92
Hart et al.	Caucasian/Australia	2010	IOT	4.2	0.641	53.1	69.8
Dewailly et al	Caucasian	2011	IOT	4.9	0.973	92	97
Homburg et al	Caucasian	2013	DSL	6.72	0.81	60.0	98.2
Casadei et al.	Caucasian/Italy	2013	IOT	4.62	0.97	95.0	95.0
Sahmay et al	Caucasian/Nordic	2013	DSL	3.94	0.92	80.0	89.8
Fong et al	Caucasian	2017	Gen II	5.5(young women <30 yrs)	0.903(young women)	82	84.1
				5(old women >30 yrs)	0.948(old women)		
Tremellen et al.	Austarlia/Caucasian	2015	Elecys automated	5.07	0.836	83.7	82.3
Pigny et al	Caucasian	2016	Automated	4.2	0.93	(1 <del></del> )	92
			Manual	5.6			
Iliodromiti et al	Metaanalysis	2013	IOT	4.7	0.87	82.8	79.4

#### Dr. Rana Choudhary

Mahajan N et al. Establishing an Anti-Müllerian hormone cutoff for diagnosis of polycystic ovarian syndrome in women of reproductive age-bearing Indian ethnicity using automated AMH assay. J Hum Reprod Sci. June 2019

### **Optimum cut off values for AMH in PCOS**


- Ethnic & racial differences in ovarian reserve
- Indian ethnicity AMH > 5.03 ng/mL (sensitivity 70.68% & specificity 79.91%)
- A much higher threshold value, however, has been given by other Asian groups

Author	Ethnicity	Year	AMH assay	AMH cut off (ng/ml)	AUC	Sensitivity (%)	Specificity (%)
Lin et al	Taiwan	2011	DSL	7.3	0.774	76	70
Chao et al.	Taiwan	2012	DSL	3.5		74.0	79.0
Woo et al	Korea	2012	IOT	7.82	0.86	75.9	86.8
Wiveko Budi et al	Iran	2014	Gen II	4.45	0.87	76	74.6
Song et al	Korea	2017	GEN II	10	0.876	71	93
Chao-Yan et al	Chinese	2018	Union	8.16 (20-29)	0.85	78.4	80.9
			Immunanalyser	5.89 (30-39)	0.86	82.6	79.8
Matsuzaki	Japan	2017	Elecsys	10		24.6	92.6
Mahajan & Jasneet	INDIA	2018	Elecsys	5.03	0.826	70.68	79.91


#### Dr. Rana Choudhary

Mahajan N et al. Establishing an Anti-Müllerian hormone cutoff for diagnosis of polycystic ovarian syndrome in women of reproductive age-bearing Indian ethnicity using automated AMH assay. J Hum Reprod Sci. June 2019

### Are AMH levels different in PCOS?




AMH per granulosa cell was compared between normal ovaries, ovulatory & anovulatory PCOs (Laura Pellatt et al J Clin Endocrinol Metab 92: 240–245, 2007)



AMH production was on average 75 times higher per granulosa cell from anovulatory PCOS & 20 times from ovulatory PCOS than healthy ovaries



AMH – Intrinsic property of granulosa cells in PCOS, persists even after stimulation for IVF (Catteau-Jonard et al., 2008)



个AMH concentrations are also found in follicular fluid (Das et al., 2008)

Anovulatory PCOS have 18 times higher AMH than women with ovulatory PCOS (Pellatt et al., 2010) Dr. Rana Choudhary

### Facts about AMH levels in PCOS

Cut-off values of AMH have been proposed - Varying sensitivity & specificity (Pigny et al., 2006; Lin et al., 2011)

Elevated AMH - 91.7% specificity & 79.4% sensitivity in predicting amenorrhoea when AMH was 11.4 ng/ml (Tal et al., 2014)

Higher AMH in PCOS patients with IR in comparison to PCOS without IR (Fonseca et al., 2014)

Positive correlation – AMH, HOMA-IR & Insulin levels Negative correlation - AMH & HOMA-B in both groups Relationship between AMH & IR is in- dependent of PCOS status (Nardo et al., 2009; Skalba et al. 2011)

AMH has been shown to be negatively correlated with BMI (Fleming et al., 2015) Dr. Rana Choudhary

### AMH & AFC in PCOS

- Lower rate of AMH fall increases their fertility window
- Increase in no. of recruitable follicles at an advanced age allows better ART outcomes
- Poor oocyte quality Heterogeneity of steroidogenesis between individual follicles, altered intrafollicular environment, ↑ granulosa cell apoptosis, impaired mitochondrial function due to oxidative stress & epigenetic modification

#### Dr. Rana Choudhary

Mahajan N et al. Establishing an Anti-Müllerian hormone cutoff for diagnosis of polycystic ovarian syndrome in women of reproductive age-bearing Indian ethnicity using automated AMH assay. J Hum Reprod Sci. June 2019

#### **Correlation between AMH & AFC**

Positive correlation between AMH & AFC (*P* < 0.0001) (Pigny et al., 2003)

AMH is tightly correlated with the 2 – 5 mm but not 6 – 9 mm follicular number (Pigny et al., 2003)

AMH levels are increased & tend to be associated with LH levels in PCOS (Piouka A et al 2010)

AMH had negative correlation with FSH concentration (P < 0.04) (Pigny et al., 2003)Did not correlate with serum FSH levels (Piouka A et al 2010)Dr. Rana Choudhary

### **AMH & AFC in PCOS - Conclusion**

- Sr AMH > 5.03 ng/mL done on automated assay (Indian origin)
- AMH Differentiate between PCOS phenotypes
- PCOS & polycystic ovarian morphology (PCOM) Higher response to gonadotropin & higher total no. of mature oocytes

Serum AMH is likely to emerge as an important marker of PCOS

May replace PCOM in diagnostic criteria for women of reproductive age group

Mahajan N et al. Establishing an AMH cutoff for diagnosis of PCOS in women of reproductive age-bearing Indian ethnicity using automated AMH assay. J Hum Reprod Sci. June 2019


### **Recommendations - PCOS**

- AMH should not yet be used as an alternative for detection of PCOM / PCOS (EBR)
- With improved standardisation of assays & established cut off levels (large scale validation) AMH may become more accurate in detection of PCOM (CPP)
- Indian PCOS Higher infertility & Lower live birth rates following IVF (CCP)


- 1. Helena Teede et al. International evidence based guideline for the assessment & management of PCOS **2018** (CREPOS, Monash University, ASRM, ESHRE)
- Malik, et al.: Management of PCOS in India. A Consensus Evidence-based Good Clinical Practice Recommendations. April 2015
  Dr. Rana Choudhary
- 3. Mehta J, Kamdar V, Dumesic D. Phenotypic expression of polycystic ovary syndrome in South Asian women. Obstet. Gynecol. Surv. 2013

# Any association between candidate gene in PCOS & Ovarian response?

genetic predisposition to secrete excess androgen



#### Candidate genes in PCOS that influence ovarian response



- CYP17 (P450c17)
- CYP19 (P450arom)

Metabolic: insulin secretion and action; obesity

- Beta cell function: TCF7L2, KCNJ11
- •Insulin resistance: IR, PPARγ

•Obesity: FTO

Androgen action Androgen receptor

**Ovarian follicle development** 

Follistatin; FBN3

#### Candidate genes in PCOS that influence ovarian response

"Genome-wide association study identifies susceptibility loci for PCOS on chromosome 2p16.3, 2p21 and 9q33.3"


Fat mass and obesity associated gene present on Chromosome 16 may be affected LHGCR and FSHR are both located on 2p21 Chen et al, Nature Genetics 2011 43 55-59 FBN3 expression in human fetal ovary may be affected Hatzirodos et al FASEB 2011 Mar 16.


Alterations in FBN3 expression occur in other organs or tissues such as the anterior pituitary, influencing hormonal regulation of the ovary or adipose tissue.

Markers in the region of chromosome 19p13.2 are associated with PCOS and FBN3 expression occurs in other organs *Dr. Rana Choudhary* 


Mark J. Prodoehl; Molecular Human Reproduction, 2009

## **Diagnosis & Therapeutic role of AMH & AFC in PCOS**





AMH – To Establish treatment protocols, in particular to define strategy for OI in infertile oligo-anovulatory PCOS women




### AMH & AFC is of value in predicting OHSS

(Broer et al., 2011a)

Dr. Rana Choudhary

## **Prior level AMH predicting hyper-response**



# Prior Prediction of hyperresponse (>20 oocytes) with use of AFC better: a good balance between false positive rates & sensitivity

Table 6: Sensitivity, specificity, positive predictive value (PPV) for positive test results and proportion of patients (accuracy) with a correct prediction at different cut off levels for the total antral follicle count (AFC) for the prediction of 'hyper'response in IVF.

Total AFC	Sensitivity	Specificity	PPV	Accuracy
> 10	0.94	0.71	0.36	0.76
> 12	0.88	0.80	0.44	0.81
>   4	0.82	0.89	0.58	0.88
>  6	0.47	0.96	0.67	0.88
> 18	0.29	0.98	0.71	0.87
- 10	0.27	0.70	0.71	0.07

**Optimum Cut off value for AFC = >14** 

Sensitivity 82 %

Specificity 89 %

*Kwee, RBE* **2007** 



## Sensitivity, specificity, positive and negative predictive values for prediction of high ovarian response at optimum cut off levels of variables

Variable	AUC	Cutoff value	Sensitivity(%)	Specificity(%)	PPV	NPP
Age(y)	0.409(0.312-0.506)	26.5	58	30	0.39	0.72
BMI(Kg/m <sup>2</sup> )	0.468(0.362-0.574)	24.1	67	42	0.25	0.64
Basal FSH(mIU/mL)	0.385(0.294-0.475)	5.05	51	36	0.37	0.72
Basal E2(pg/mL)	0.474(0.377-0.572)	43.5	69	33	0.31	0.68
AMH(pmol/l)	0.922(0.876-0.968)	34.5	93	78	0.65	0.96
Small AFC(n)	0.961(0.933-0.989)	16	89	92	0.83	0.94

Table 3 Comparison of performance of variables for high ovarian response by ROC curve analysis

PPV positive predictive value, NPP negative predictive value

Sensitivity and specificity for prediction of high ovarian response were 89 % and 92 %

for small AFC and 93% and 78% for AMH at the cut off values of  $\geq$  16 and  $\geq$  34.5 Dr. Rana Choudharv pmol/l, (4.86 ng/ml) respectively

J Assist Reprod Genet (2009)

# **Predicting Response & LBR with AMH levels**

Ovulation & PRs were significantly higher with CC (97% P < 0.001, 46% P = 0.034) in patients with low AMH (<3.4 ng/ml) vs AMH 3.4 ng/ml or greater (48% & 19%)

(Mahran et al., 2013)

AMH was a weak predictor of live birth outcome in patients following IVF

(lliodromiti et al., 2014)

Day 3 AMH ≥3.2 ng/ml was a predictor of IR (72.1% sensitivity, 72.7% specificity) & CPR (75.6% sensitivity, 77.3% specificity)

(Kaya et al., 2010)

AMH - 7.7 ng/ml was predictive of ovulation following LOD (78% sensitivity & 76% specificity) *Dr. Rana Choudhary* 

(Amer et al., 2009)

## **Ovarian Reserve Test & Predicting Response to COS**


Tests	Low response	High Response
AFC	< / = 4	> 16
AMH	< / = 5.4 pmol/l	>/=25.0 pmol/l
FSH	> 8.9 IU/I	< 4 IU/I


Dr. Rana Choudhary

Fertility problems: Assessment and treatment. **NICE Reference Clinical guideline [CG156].** Feb 2013. Last updated: Sept **2017** Assessing & managing ovulation disorders. **NICE** Pathway last updated: April **2018** 

POSEIDON Group Labelled Patients with POR as Low Prognosis Group

## POR must be categorized by age & ovarian reserve





# **POSEIDON** Criteria is based on FORT

Ratio of pre-ovulatory follicle (16–22mm in diameter) count (PFC) on hCG day × 100 Small antral follicle (3–8mm in diameter) count at baseline

- Ovarian sensitivity to gonadotropins differs from a patient to another
- Evaluates ovarian sensitivity to FSH
- Follicular Output Rate (FORT) Efficient quantitative & qualitative marker of ovarian responsiveness to gonadotropins - Decision of treatment protocol, gonadotropin stimulation doses for hyporesponders

#### Dr. Rana Choudhary

Michael Grynberg. Understanding Follicular Output Rate (FORT) & its Implications for POSEIDON Criteria. Frontiers in Endocrinology. April 2019

# Prediction of IVF/ICSI outcome based on FORT



Table 4Characteristics, ovarian stimulation data and IVF/ICSI outcomes of PCOS patients according to FORT.

	Low FORT	Medium FORT	High FORT	P-value
	(<0.5; n = 45)	(0.5–0.73; n = 56)	(>0.73; n = 39)	
Age (years)	32 ± 4	32 ± 3	33 ± 4	NS
Duration of infertility (years)	5 ± 3	6 ± 3	5 ± 4	NS
Body mass index (kg/m <sup>2</sup> )	25.72 ± 3.70	25.60 ± 3.87	24.34 ± 3.17	NS
FSH/LH ratio	$1.04 \pm 0.58$	0.84 ± 0.53	$0.82 \pm 0.52$	NS
Serum testosterone (ng/ml)	0.38 ± 0.16	0.37 ± 0.20	0.36 ± 0.19	NS
Serum basal oestradiol (pg/ml)	39.73 ± 19.66	39.53 ± 21.32	43.89 ± 26.38	NS
AFC	22.36 ± 5.86	19.86 ± 5.72	16.44 ± 4.94	<0.001
Dose of starting FSH (IU)	208.61 ± 59.10	228.57 ± 64.08	227.24 ± 54.33	NS
Duration of gonadotrophin (days)	10.04 ± 1.94	8.68 ± 0.96	8.64 ± 0.96	<0.001
Total gonadotrophin dose (IU)	2116.67 ± 802.68	1974.33 ± 651.38	1879.17 ± 476.65	NS
PFC	7.93 ± 2.92	11.79 ± 3.27	15.10 ± 4.89	<0.001
Retrieved oocytes	12.04 ± 7.54	15.63 ± 7.08	17.21 ± 7.66	0.005
2PN fertilization rate	63.47 (344/542)	69.49 (608/875)	60.66 (407/671)	0.001
Good-quality embryo rate	68.06 (211/310)	72.71 (373/513)	64.99 (232/357)	0.047
Implantation rate	25.51 (25/98)	31.67 (38/120)	27.59 (24/87)	NS
Clinical pregnancy rate	46.67 (21/45)	53.57 (30/56)	38.46 (15/39)	NS

#### • Number of retrieved oocytes was highest in high FORT group (P < 0.05)

- Fertilisation Rate & good-quality were significantly higher in medium FORT group (P < 0.05)</li>
  - Dr. Rana Choudhary
    Better IVF/ICSI outcome was achieved in PCOS patients with medium FORT values

Ning Zhang. RBM online 2013

# PCOS: Reproductive outcome & Ovarian reserve

Long-term follow-up of PCOS patients

1,6

0.4

0.0


-0,2

Log Ovarian Volume

□— PCOS

--- Controls

- To evaluate relationship between ulletovarian volume, no. of antral follicles, AMH, PCOS status & Age, pre and post-menopausal PCOS patients with controls without hormonal treatment
  - Ovarian reserve declined at a similar rate with age in both groups (P<0.001)
  - PCOS patients had a better ovarian reserve across ages compared with controls (P<0.001 ovarian reserve variable)



Log Number of Antral Follicles

2,0

1,5

1.0

0.0

2,5

35

40

45

Age

50

55

60

## Conclusion

Young women with PCOS  $- \uparrow$  Ovarian reserve compared with age-matched controls

Polycystic ovaries are larger & contain more antral follicles as assessed by USG Higher levels of AMH in women with PCOS than in controls

AMH is crucial in maintaining right tempo of folliculogenesis in ovary making it one of the most important ovarian hormones & crucial factors underpinning female fertility

AMH - Best biochemical marker of ovarian function

Easy measure of submerged part of iceberg of follicle growth ('acyclic' ovarian activity)

Highly elevated AMH - Predictive of poor response to various Rx of PCOS including weight loss, OI & LOD. But do not predict LBR *Dr. Rana Choudhary*